Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 3.

Delord, Jean-Pierre; Robert, Caroline; Nyakas, Marta; McArthur, Grant A; Kudchakar, Ragini; Mahipal, Amit; Yamada, Yasuhide; Sullivan, Ryan J; Arance, Ana; Kefford, Richard F; Carlino, Matteo S; Hidalgo, Manuel; Gomez-Roca, Carlos; Michel, Daniela; Seroutou, Abdelkader; Aslanis, Vassilios; Caponigro, Giordano; Stuart, Darrin; Moutouh-de Parseval, Laure; Demuth, Tim; Dummer, Reinhard (2017). Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clinical Cancer Research:1-38.

Lorigan, Paul; Ascierto, Paolo A; Dummer, Reinhard; Eggermont, Alexander M; Flaherty, Keith T; Garbe, Claus; Gogas, Helen; Hauschild, Axel; Kefford, Richard F; Kirkwood, John M; Larkin, James; Long, Georgina V; Maio, Michele; McArthur, Grant A; Ribas, Antoni; Robert, Caroline; Schadendorf, Dirk; Sondak, Vernon K; Wolchok, Jedd D; Hudson, Andrew M (2015). Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncology, 16(1):15-17.

Falchook, Gerald S; Long, Georgina V; Kurzrock, Razelle; Kim, Kevin B; Arkenau, Tobias H; Brown, Michael P; Hamid, Omid; Infante, Jeffrey R; Millward, Michael; Pavlick, Anna C; O'Day, Steven J; Blackman, Samuel C; Curtis, C Martin; Lebowitz, Peter; Ma, Bo; Ouellet, Daniele; Kefford, Richard F (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet, 379(9829):1893-1901.

This list was generated on Thu Dec 14 01:59:30 2017 CET.